[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561007":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":61,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":25,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":25,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"The University of New South Wales","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Lactobacillus Paracasei LPB27","EXPERIMENTAL","Formulation: Lactobacillus paracasei LPB27 (10 billion cfu\u002F serve) and Maltodextrin (up to 1g).\n\nDosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food.",[13],"Dietary Supplement: Lactobacillus Paracasei LPB27",{"label":15,"type":16,"description":17,"interventionNames":18},"Maltodextrin","PLACEBO_COMPARATOR","Formulation: Maltodextrin 1g\n\nDosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food.",[19],"Other: Maltodextrin",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Probiotic",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo",[15],[30],{"name":31,"affiliation":32,"role":33},"Keith CY Ooi","University of New South Wales","PRINCIPAL_INVESTIGATOR",[35,40],{"name":31,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","9382 1752","02","keith.ooi@unsw.edu.au",{"name":41,"role":36,"phone":37,"phoneExt":38,"email":42},"Jessica Halim","lacestudy_SCH@unsw.edu.au",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Sydney Children's Hospital","RECRUITING","Randwick","New South Wales","2031","Australia","AU",{"type":53,"coordinates":54},"Point",[55,56],151.24895,-33.91439,{"lat":56,"lon":55},[59],{"name":60,"role":36,"phone":25,"phoneExt":25,"email":25},"Linda Martin",{"type":33,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Keith Chee Y. Ooi","Professor",[65],{"name":66,"class":67},"Evolution Health Pty Ltd","UNKNOWN","100561007","phase-2-lace-lactobacillus-paracasei-lpb27-on-early-childhood-eczema-100561007",false,"NCT06584552","LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)","Lactobacillus Paracasei LPB27 On Early Childhood Eczema","Inclusion Criteria:\n\n* Age: 3 months to 3 years old\n* Diagnosis: Eczema (atopic dermatitis) diagnosed clinically by a paediatric dermatologist or immunologist.\n* Severity: Investigator Global Assessment for Atopic Dermatitis (IGA) severity of 1-3 (almost clear, mild, moderate) and a SCORAD score greater than 8.7.\n* Willingness and ability of the subject to comply with the protocol requirements.\n\nExclusion Criteria:\n\n* Patients on systemic immunosuppression and\u002For biologic agents (participants who start systemic immunosuppression and\u002For biologic agents mid-way through the study will be considered to have not achieved treatment success and will be withdrawn, regardless of their SCORAD index scores).\n* Mothers who are breastfeeding and on probiotics but not willing to stop probiotics.\n* Child already on probiotics and parents not willing to stop during the entire study period (washout period of 4 weeks; including formulas that contains probiotics).\n* Eczema complicated by active skin infection e.g. impetigo\u002Fcellulitis\u002F eczema herpeticum (can be considered once active infection resolved).\n* Child currently on oral or IV antibiotics (washout period of 4 weeks allowable once antibiotics completed). Participants who require antibiotics after being enrolled in the study may continue on the study as usual.\n* Immunodeficient disorders.\n* Chronic disorder involving the gastrointestinal tract (e.g., inflammatory bowel disease, short gut syndrome, cystic fibrosis).\n* Known hypersensitivity to components contained in study product.","ALL","3 Months","3 Years",{"count":79,"type":80},100,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.",[86,87],"Eczema","Allergy",[89,90,91],"Immunology","Microbiome","Paediatrics","2025-05-28",{"date":94,"type":95},"2025-06-03","ACTUAL",{"date":97,"type":95},"2024-11-15",{"date":99,"type":80},"2026-09",{"name":5,"class":6},1]